Zhenyu Xu Sells 4,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Insider sale: SOPHiA GENETICS insider Zhenyu Xu sold 4,000 shares on July 13 at an average price of $5.70, totaling $22,800. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Stock and financial snapshot: SOPH fell 0.7% to $5.68 in Tuesday trading, with a market cap of $476.5 million. The company recently reported a quarterly loss of $0.27 per share, wider than expected, though revenue came in above estimates at $21.69 million.
• Wall Street view: Analyst sentiment is mixed, with two Buy ratings and one Sell rating, but MarketBeat’s average rating remains Hold. The average price target is $7.50, above the current share price.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $5.70, for a total value of $22,800.00. Following the sale, the insider owned 610,887 shares of the company's stock, valued at approximately $3,482,055.90. This represents a 0.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.
• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $3,167.68.

SOPHiA GENETICS Stock Down 0.7%

SOPH traded down $0.04 during midday trading on Tuesday, hitting $5.68. 120,863 shares of the company's stock traded hands, compared to its average volume of 190,422. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a market cap of $476.50 million, a PE ratio of -10.92 and a beta of 0.96. The stock's fifty day simple moving average is $5.18 and its 200-day simple moving average is $4.99. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the company. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the 4th quarter worth $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter worth $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the 4th quarter worth $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS during the fourth quarter valued at about $55,000. Institutional investors own 31.59% of the company's stock.

Analyst Ratings Changes

SOPH has been the subject of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a "buy" rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and an average target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.